Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications

NCT06573008 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06573008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06573008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications
Lead sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
November 11, 2024
Completion date
December 30, 2025
Enrollment
328 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human